# Vaxart (VXRT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VXRT
## Company Profile
- Ticker: VXRT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Vaccines
## Stock Data
- Close: 0.4925 USD
- Market cap: Not available USD
- Last updated: 2026-09-03
## Business Overview
### Oral Vaccine Platform
Vaxart is a clinical-stage biotechnology company developing recombinant vaccines delivered as pills. Its platform is designed to eliminate injections and enable products that can be stored and shipped without refrigeration.
### Mucosal Immunization Approach
The delivery technology combines an adenoviral vector with a TLR3 agonist to stimulate immune responses at mucosal surfaces. Vaxart aims to create oral alternatives to existing injectable vaccines and vaccines for indications without established products.
### COVID-19 Program
The lead Phase 2b program compares Vaxart's oral COVID-19 vaccine with an approved mRNA vaccine. A 400-participant sentinel cohort assessed safety before analysis of the approximately 5,000-participant main cohort.
### Broader Vaccine Pipeline
Additional development programs target norovirus and influenza, while a therapeutic HPV vaccine represents the platform's first immuno-oncology application.
## Why The Stock Is Moving

As of Sep 3, 2026, VXRT closed up 0.41% at $0.4925. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline efficacy and safety results from the complete Phase 2b COVID-19 study in the first half of 2027.

## Recent News
- 2026-08-26 20:07 EST — [Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology](https://biopharmsignal.com/news/VXRT/vaxart-expands-intellectual-property-portfolio-with-european-patent-protecting-p-0c41eb53) — Source: Vaxart
- 2026-08-06 20:05 EST — [Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/VXRT/vaxart-provides-business-update-and-reports-second-quarter-2026-financial-result-f6dfcbb4) — Source: Vaxart
- 2026-07-30 12:00 EST — [Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET](https://biopharmsignal.com/news/VXRT/vaxart-to-host-stockholder-fireside-chat-on-august-7-at-4-30-p-m-et-1f079317) — Source: Vaxart
- 2026-07-21 12:00 EST — [Vaxart to Participate in BTIG Biotechnology Conference 2026](https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-biotechnology-conference-2026-f2702b19) — Source: Vaxart
- 2026-07-17 20:05 EST — [Vaxart Announces Results of Annual Meeting of Stockholders](https://biopharmsignal.com/news/VXRT/vaxart-announces-results-of-annual-meeting-of-stockholders-25ca999f) — Source: Vaxart